Late-stage functionalization with strain-release warheads enables tunable covalent inhibition

Covalent inhibition continues to gain momentum as a strategy for selective protein modulation in both therapeutic and chemical biology contexts. Covalent reactive groups (CRGs) typically engage nucleophilic residues such as cysteine, resulting in targeted protein inactivation. However, common electrophiles such as acrylamides often suffer from nonselective reactivity, leading to off-target effects and toxicity. To overcome these limitations, we developed a modular sulfur(IV) reagent platform for the mild, late-stage installation of sulfonyl- and sulfonimidoyl-bicyclobutane motifs with complete cysteine selectivity. This methodology enables access to diverse sulfur(VI) CRGs with tunable strain-release reactivity. Incorporation into US Food and Drug Administration-approved covalent inhibitors demonstrated effective bioisosteric replacement of acrylamides and the potential of strain-release CRGs for selective protein targeting. Preclinical studies in mice have validated this approach, highlighting its promise for next-generation covalent drug design.

Authors

Institutions

Publication Details

Journal
Science
Published
2026-07-23
DOI
https://doi.org/10.1126/science.adx7219
Primary Topic
Click Chemistry and Applications
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Late-stage functionalization with strain-release warheads enables tunable covalent inhibition

Yun‐Pu Chang, Victoria Izumi, John M. Koomen, Thomas Scattolin et al.
Science
Click Chemistry and Applications
article

Late-stage functionalization with strain-release warheads enables tunable covalent inhibition

Yun‐Pu Chang, Victoria Izumi, John M. Koomen, Thomas Scattolin, Andrii Monastyrskyi, Samer Sansil, E. Schönbrunn, Zachary P. Shultz, Ramu Kakumanu, Dylan Grassie, Łukasz Wojtas, Luxin Sun, Alessio Gabellini, Justin M. Lopchuk, Bin Fang, Ansar Lee-Sam, Derek Duckett, Kyle Pedretty
article en

Abstract

Covalent inhibition continues to gain momentum as a strategy for selective protein modulation in both therapeutic and chemical biology contexts. Covalent reactive groups (CRGs) typically engage nucleophilic residues such as cysteine, resulting in targeted protein inactivation. However, common electrophiles such as acrylamides often suffer from nonselective reactivity, leading to off-target effects and toxicity. To overcome these limitations, we developed a modular sulfur(IV) reagent platform for the mild, late-stage installation of sulfonyl- and sulfonimidoyl-bicyclobutane motifs with complete cysteine selectivity. This methodology enables access to diverse sulfur(VI) CRGs with tunable strain-release reactivity. Incorporation into US Food and Drug Administration-approved covalent inhibitors demonstrated effective bioisosteric replacement of acrylamides and the potential of strain-release CRGs for selective protein targeting. Preclinical studies in mice have validated this approach, highlighting its promise for next-generation covalent drug design.

ScienceVol. 393(6809)
University of South Florida (US), Moffitt Cancer Center (US), Molecular Oncology (United States) (US)
National Cancer Institute, National Institute of General Medical Sciences
Zero hunger
Openalex Percentile: Top 16%
Click Chemistry and Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.